npj Primary Care Respiratory Medicine (Sep 2022)

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma

  • Leanne Kaye,
  • Vy Vuong,
  • Meredith A. Barrett,
  • Elroy Boers,
  • Theresa Guilbert

DOI
https://doi.org/10.1038/s41533-022-00299-3
Journal volume & issue
Vol. 32, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medication use and may reduce symptom-related disruptions.